Standard Treatments of Very-early Stage Hepatocellular Carcinoma

Naval Military Medical University (Second Military Medical University)

Status: Completed

Conditions: Hepatocellular Carcinoma; Very-early Stage

Treatments: Procedure: RFA; Procedure: PEI; Procedure: MWV

Study type: Interventional

Funder types: Other

Identifiers

NCT02728193

2012ZX10002016003001

Details and patient eligibility

About

The aim of our study was to elucidate the difference in the rates of complication, hospitalization days, medical expenses, MRI showed that the degree of tumor necrosis, and overall survival rates of the therapies between PEI, MVA and RFA, and make the standard for minimally invasive treatment of very early stage HCC.

Enrollment: 300 patients

Sex: All

Ages: 18 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Preoperative clinical, imaging and tumor markers were diagnosed as hepatocellular carcinoma
2. Tumor diameter<2cm
3. Child-Pugh class A liver function
4. Without major organ dysfunction
5. male or female patients > 18 years and <=70 years of age
6. Voluntary participation in this clinical trial

Exclusion criteria

1. Other anticancer treatment before therapy
2. Patients with apparent major organs (i.e. cardiac, pulmonary, cerebral and renal) dysfunction, which may affect the treatment of liver cancer
3. Patients with other diseases that may affect the treatment of this treatment
4. History of other malignant tumors
5. Patients who are participating in other clinical trials
6. Pregnant, lactating women

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

300 participants in 3 patient groups

RFA

Experimental group

Description:

Radiofrequency ablation

Treatment:

Procedure: RFA

MWV

Experimental group

Description:

Microwave ablation

Treatment:

Procedure: MWV

PEI

Experimental group

Description:

Percutaneous ethanol injection

Treatment:

Procedure: PEI